KEMADRIN (procyclidine hydrochloride) is indicated in the
treatment of parkinsonism including the postencephalitic, arteriosclerotic,
and idiopathic types.
Partial control of the parkinsonism symptoms is the
usual therapeutic accomplishment.
Procyclidine hydrochloride is usually more
efficacious in the relief of rigidity than tremor; but tremor, fatigue, weakness,
and sluggishness are frequently beneficially influenced.
It can be substituted
for all the previous medications in mild and moderate cases.
For the control
of more severe cases, other drugs may be added to procyclidine therapy as
indications warrant.Clinical reports indicate that
procyclidine often successfully relieves the symptoms of extrapyramidal dysfunction
(dystonia, dyskinesia, akathisia, and parkinsonism) which accompany the therapy
of mental disorders with phenothiazine and rauwolfia compounds.
to minimizing the symptoms induced by tranquilizing drugs, the drug effectively
controls sialorrhea resulting from neuroleptic medication.
At the same time,
freedom from the side effects induced by tranquilizer drugs, as provided by
the administration of procyclidine, permits a more sustained treatment of
the patient’s mental disorder.Clinical results
in the treatment of parkinsonism indicate that most patients experience subjective
improvement characterized by a feeling of well-being and increased alertness,
together with diminished salivation and a marked improvement in muscular coordination
as demonstrated by objective tests of manual dexterity and by increased ability
to carry out ordinary self-care activities.
While the drug exerts a mild atropine-like
action and therefore causes mydriasis, this may be kept minimal by careful
adjustment of the daily dosage.
-- A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
-- An indication that a person has a condition or disease. Some examples of symptoms are headache, fever, fatigue, nausea, vomiting, and pain.
-- Continuous involuntary sustained muscle contraction which is often a manifestation of BASAL GANGLIA DISEASES. When an affected muscle is passively stretched, the degree of resistance remains constant regardless of the rate at which the muscle is stretched. This feature helps to distinguish rigidity from MUSCLE SPASTICITY. (From Adams et al., Principles of Neurology, 6th ed, p73)
-- Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.
-- The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
-- Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.
-- An attitude or posture due to the co-contraction of agonists and antagonist muscles in one region of the body. It most often affects the large axial muscles of the trunk and limb girdles. Conditions which feature persistent or recurrent episodes of dystonia as a primary manifestation of disease are referred to as DYSTONIC DISORDERS. (Adams et al., Principles of Neurology, 6th ed, p77)
-- Acquired and inherited conditions that feature DYSTONIA as a primary manifestation of disease. These disorders are generally divided into generalized dystonias (e.g., dystonia musculorum deformans) and focal dystonias (e.g., writer's cramp). They are also classified by patterns of inheritance and by age of onset.
-- Abnormal involuntary movements which primarily affect the extremities, trunk, or jaw that occur as a manifestation of an underlying disease process. Conditions which feature recurrent or persistent episodes of dyskinesia as a primary manifestation of disease may be referred to as dyskinesia syndromes (see MOVEMENT DISORDERS). Dyskinesias are also a relatively common manifestation of BASAL GANGLIA DISEASES.
-- Problems that occur when treatment affects tissues or organs other than the ones meant to be affected by the treatment. Common side effects of cancer treatment are fatigue, pain, nausea, vomiting, decreased blood cell counts, hair loss, and mouth sores.